Q4 2025 Thyrocare Technologies Ltd Earnings Call Transcript
Key Points
- Thyrocare Technologies Ltd (BOM:539871) achieved a 20% year-on-year revenue growth, driven primarily by its pathology business.
- The company has expanded its franchise network to over 11,000 active franchisees, contributing to a 14% increase in test volumes.
- Thyrocare Technologies Ltd (BOM:539871) is India's first and only 100% NABL accredited national laboratory chain, reflecting its commitment to quality.
- The company has successfully integrated acquisitions such as Polo Labs and Vimta Labs, enhancing its presence in North and South India.
- Thyrocare Technologies Ltd (BOM:539871) has launched new specialized tests and expanded its test menu, contributing to higher revenue realization.
- The company's effective tax rate is expected to be around 28% to 29%, which could impact net profitability.
- There is a potential risk of margin pressure due to competitive pricing strategies from organized and unorganized players.
- The receivables have increased significantly, partly due to extended credit periods offered to partners.
- The company's expansion into new geographies, such as Tanzania, is still in its nascent stages and may take time to contribute significantly to revenue.
- Thyrocare Technologies Ltd (BOM:539871) faces challenges in maintaining high EBITDA margins amidst ongoing investments in specialized tests and new labs.
Ladies and gentlemen, good day and welcome to the Thyrocare Technologies Ltd earnings conference call. As a reminder, all participant lines will be in the listen-only mode (Operator Instructions) I now hand the conference over to Mr. Kapil Gupta from Thyrocare Technologies Limited. Thank you and over to you.
Thank you, [Yesashi]. A very good evening to all and thank you for joining us today for the Thyrocare earnings conference call for Q4 and annual results of FY25. Today we have with us Mr. Rahul Guha, MD and CEO of Thyrocare, Mr. Alok Kumar Jagnani, CFO of Thyrocare, and Mr. Nitin Chugh, Chief Commercial Officer of Thyrocare, along with other key members of the senior management on this call to share highlights of the business and finances for the quarter and the annual results.
I hope you have gone through our results release, the quarterly earnings presentation, and press release, which has now been uploaded on the stock exchange website. The transcript of this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
